Blood test breakthrough? new study hopes to sniff out liver cancer early.

NCT ID NCT07148310

Recruiting now Diagnosis Sponsor: Epiliquid Holding, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing a new blood test called delta-HLD to see if it can accurately detect liver cancer (hepatocellular carcinoma). Researchers will compare blood and tissue samples from 200 people, half with liver cancer and half with liver cirrhosis but no cancer. If the test works well, it could offer a less invasive way to catch liver cancer earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delta-HLD liquid biopsy test
What this could lead to: If successful, this could lead to a simple blood test for early detection of liver cancer, potentially improving survival rates.
What could go wrong: This is a small, early-stage study. The test may not be accurate enough, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Epiliquid
RECRUITING

Mendoza, 5500, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.